10-Q: PDS Biotech Reports Q3 2025 Results, Advances Clinical Pipeline

PDS Biotechnology Corporation reported a reduced net loss for Q3 2025, advanced multiple immunotherapy clinical trials, but raised substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $9.0 million from $10.7 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, decreased to $26.9 million from $29.7 million in the prior year period.
• Cash and cash equivalents stood at $26.2 million as of September 30, 2025, down from $41.7 million at December 31, 2024.
• Research and development expenses decreased by $2.2 million for the three months and $3.4 million for the nine months ended September 30, 2025, primarily due to reduced manufacturing and personnel costs.
• General and administrative expenses increased by $0.2 million for the three months but decreased by $0.7 million for the nine months ended September 30, 2025.
• The company initiated its VERSATILE-003 Phase 3 clinical trial for PDS0101 in HPV16-positive HNSCC in March 2025, but temporarily paused it in October 2025 to seek an expedited FDA pathway.
• Final topline survival data from the VERSATILE-002 Phase 2 trial for PDS0101 in HPV16-positive HNSCC was announced in August and September 2025, showing promising results compared to historical controls.
• The colorectal cancer cohort of a Phase 2 trial with PDS01ADC met pre-defined criteria for expansion to stage 2 in July 2025.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the filing date, with current funding projected into Q1 2026.
• The company secured $20.0 million in senior secured convertible debentures and warrants in April 2025, with approximately $19 million used to retire previous debt.
• A subsequent event in November 2025 involved a securities purchase agreement yielding approximately $4.8 million in net proceeds.

Sentiment

Score: 6

Explanation: While the company reported reduced losses and strong clinical trial data exceeding historical benchmarks, the explicit 'going concern' warning and high debt interest rate temper the overall sentiment. The clinical progress is a significant positive, but the financial sustainability remains a critical concern requiring further capital.

Positives

• Net loss decreased by $1.7 million for the three months ended September 30, 2025, and by $2.7 million for the nine months ended September 30, 2025, compared to the prior year periods.
• Research and development expenses decreased by $2.2 million (33%) for the three months and $3.4 million (19%) for the nine months ended September 30, 2025, indicating more efficient spending or completion of certain costly phases.
• Net cash used in operating activities decreased by $2.8 million for the nine months ended September 30, 2025, compared to the prior year, reflecting reduced cash burn.
• VERSATILE-002 Phase 2 trial data for PDS0101 + Keytruda showed a median Overall Survival (mOS) of 30 months (39.9 months for CPS20 patients), significantly exceeding published mOS for pembrolizumab alone (12-18 months).
• VERSATILE-002 also demonstrated an Objective Response Rate (ORR) of 35.8% (47.6% for CPS20 patients), higher than published ORR for pembrolizumab (19-25%).
• Median Progression-Free Survival (mPFS) in VERSATILE-002 was 6.3 months (14.1 months for CPS20 patients), substantially better than published mPFS of 2-3 months for approved ICIs.
• NCI-led Phase 2 trial of PDS0101 + PDS01ADC + Bintrafusp Alfa showed mOS of 42.4 months in ICI nave patients (historical 7-12 months) and 17 months in ICI resistant patients (historical 3-4 months), with an ORR of 75% in ICI nave patients (historical 11-24%).
• The colorectal cancer cohort of a Phase 2 trial with PDS01ADC met pre-defined criteria for expansion to stage 2, indicating positive initial results.
• FDA clearance of the IND application for PDS0103 and PDS01ADC in metastatic colorectal cancer was received in March 2025, advancing a new product candidate.
• Preclinical data for the Infectimune universal flu program demonstrated complete protection against sickness after lethal challenge with live SARS-CoV-2 or influenza viruses, highlighting platform potential.

Negatives

• The company continues to incur significant net losses, with an accumulated deficit of $209.0 million as of September 30, 2025.
• Cash and cash equivalents decreased by $15.5 million during the nine months ended September 30, 2025, indicating continued cash burn.
• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the filing date.
• The company's current cash resources, even with recent capital raises, are only projected to fund operations into the first quarter of 2026.
• The company is subject to restrictive covenants under its senior secured convertible debentures, including maintaining a minimum cash balance and limitations on incurring new debt or granting liens.
• The effective annual interest rate on the Debentures is approximately 24.1%, representing a high cost of debt.
• The company has reached the lifetime cap of $20 million for the New Jersey Technology Business Tax Certificate Transfer NOL program and will no longer be eligible to participate, eliminating a source of non-dilutive funding.
• The VERSATILE-003 Phase 3 clinical trial was temporarily paused in October 2025 to seek an expedited FDA pathway, which could introduce delays or uncertainty.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the date of the financial statements.
• Future operations are dependent on successfully securing additional capital through equity or debt financing, collaborations, strategic alliances, or license agreements, which are not assured.
• Failure to obtain adequate financing could lead to delays, reductions, or termination of research and development programs, or granting rights to third parties for development and marketing.
• Operating activities may be restricted by covenants related to the senior secured convertible debentures, including maintaining a minimum cash balance (lesser of $15.0 million or outstanding principal + $3.0 million).
• A breach of debt covenants could result in an event of default, allowing lenders to declare all outstanding amounts immediately due and payable and proceed against the company's assets.
• The company operates in a period of global economic uncertainty, geopolitical conflicts, and capital markets disruption, which could adversely affect its business, financial condition, and ability to access capital.
• Changes in U.S. regulatory policies, including tariffs, trade policies, or new regulations affecting the pharmaceutical industry (e.g., drug pricing, restrictions on contracting with Chinese companies), could impact operations and revenues.
• The use of artificial intelligence by vendors or bad actors poses security risks to confidential information, proprietary information, and personal data, potentially leading to reputational harm or liability.
• The company has no commercially approved products and expects to incur operating losses for the foreseeable future, with no assurance of future profitability.

Future Outlook

The company expects to continue incurring operating losses for the foreseeable future and may never become profitable. It plans to fund operations through additional equity and/or debt financings, collaborations, strategic alliances, or license agreements. Current cash resources, including recent capital raises, are projected to fund operating expenses and capital expenditure requirements into the first quarter of 2026. The company is evaluating the impact of new accounting standards and is working with the NCI to determine the best pathway for prioritized PDS01ADC studies and evaluating its use with other Versamune-based clinical candidates. The company is seeking an expedited FDA pathway for its VERSATILE-003 Phase 3 clinical trial, which could impact its design and timeline.

Management Comments

• "We believe our investigational targeted immunotherapies have the potential to overcome limitations of current immunotherapy approaches through effective conversion of the immune suppressive tumor to an immunogenic microenvironment in addition to the induction of the right type, potency and quantity of tumor-targeting killer (CD8) T cells."
• "We believe that our proprietary combinations of Versamune and PDS01ADC together with immune checkpoint inhibitors or other standards of care, may enhance the proliferation, potency and longevity of antigen specific multifunctional CD8 T cells in the tumor microenvironment and work synergistically to inhibit or treat cancer."
• "We believe that the key differentiating attributes of the Infectimune platform technology are strong induction of CD8 and CD4 T cells as well as antibodies which can be leveraged to improve treatment and preventive options in several infectious disease indications."
• "We have concluded that substantial doubt exists about our ability to continue as a going concern for a period of at least 12 months from the date of the issuance of these unaudited Condensed Consolidated Financial Statements."

Industry Context

PDS Biotech operates in the highly competitive and rapidly evolving clinical-stage immunotherapy sector, focusing on oncology and infectious diseases. Its strategy involves developing proprietary platforms (Versamune, PDS01ADC, Infectimune) to enhance the immune system's ability to target and destroy diseased cells. The company's approach of combining its therapies with established immune checkpoint inhibitors (like Keytruda/pembrolizumab) aligns with a broader industry trend towards combination therapies to improve efficacy and overcome resistance in advanced cancers. The pursuit of universal influenza vaccines also positions it within a high-need area of infectious disease prevention, leveraging T-cell responses for broader and more durable protection, a focus shared by entities like NIAID. The significant clinical data reported, particularly the improved survival and response rates compared to monotherapy ICIs, suggests potential differentiation within the crowded oncology immunotherapy space, if these results are confirmed in larger trials.

Comparison to Industry Standards

• VERSATILE-002 Phase 2 trial for PDS0101 + Keytruda showed a median Overall Survival (mOS) of 30 months (39.9 months for CPS20 patients), significantly exceeding published mOS for pembrolizumab alone (12-18 months).
• The Objective Response Rate (ORR) of 35.8% (47.6% for CPS20 patients) in VERSATILE-002 was higher than published ORR for pembrolizumab (19-25%).
• Median Progression-Free Survival (mPFS) of 6.3 months (14.1 months for CPS20 patients) in VERSATILE-002 was substantially better than published mPFS of 2-3 months for approved ICIs.
• The NCI-led Phase 2 trial of PDS0101 + PDS01ADC + Bintrafusp Alfa demonstrated a median OS of 42.4 months in immune checkpoint inhibitor (ICI) nave patients, compared to historical published results of 7-12 months for similar patients.
• In ICI resistant patients, the NCI-led trial showed a median OS of 17 months, significantly higher than historical published results of 3-4 months.
• The confirmed objective response rate (ORR) of 75% in HPV16-positive ICI nave patients in the NCI-led trial was substantially higher than historical published results of 11-24%.

Corporate Governance

Legal Proceedings

• The company is currently not a party to, and its property is not currently the subject of any material pending legal proceedings.

Related Party Transactions

• Two of the company's directors participated in the February 2025 Offering, purchasing 30,121 shares of common stock in aggregate at an offering price of $1.66 per share and common stock warrants to purchase 30,121 shares of common stock with an exercise price of $1.53 per share.

Stakeholder Impact

• Shareholders face significant dilution risk from ongoing and future equity financings, as well as the risk associated with the 'going concern' warning.
• Employees benefit from stock-based compensation plans and 401(k) contributions, but job security could be impacted by the company's liquidity challenges.
• Creditors (holders of the Debentures) have senior secured convertible debentures with a high effective interest rate and restrictive covenants, providing some protection but also exposure to the company's going concern risk.
• Patients and the medical community could benefit from the potential of the company's immunotherapy candidates, especially given the promising clinical trial results compared to existing treatments.
• Suppliers and vendors face potential payment risks due to the company's liquidity concerns, although accounts payable increased, suggesting active operations.

Next Steps

• Continue to seek additional capital through equity or debt financings, collaborations, strategic alliances, or license agreements.
• Engage with the FDA regarding the proposed amendment to the VERSATILE-003 Phase 3 clinical trial design to include progression-free survival as an early primary endpoint.
• Resume enrollment and progression of the VERSATILE-003 Phase 3 clinical trial following FDA review.
• Continue evaluation of long-term patient survival in the NCI-led Phase 2 trial of PDS0101 + PDS01ADC + Bintrafusp Alfa.
• Continue actively recruiting patients for the MD Anderson (IMMUNOCERV) Phase 2 Investigator Initiated Trial.
• Continue the Mayo Clinic IIT (MC200710) for PDS0101 alone or in combination with Keytruda in HPV-positive oropharyngeal cancer.
• Work closely with the NCI to determine the best pathway forward for prioritized PDS01ADC studies and evaluate its use in combination with other Versamune-based clinical candidates.
• Evaluate the impact of recently issued FASB ASUs on consolidated financial statements.

Key Dates

Recommendation

While PDS Biotech has demonstrated compelling clinical data for its immunotherapy candidates, showing superior outcomes compared to current standards of care in several trials, the 'going concern' warning presents a significant overhang. The company's cash runway is limited to Q1 2026, necessitating further capital raises which will likely lead to additional shareholder dilution. The high interest rate on its current debt also adds financial pressure. The positive clinical developments provide a strong foundation for future value, but the immediate financial uncertainty and the need for substantial additional funding introduce considerable risk. A 'hold' recommendation acknowledges the promising pipeline while cautioning investors about the material financial risks and the potential for further dilution until a clear path to sustainable funding is established or a major partnership is secured.

Keywords

Immunotherapy, Oncology, HPV-associated cancers, Head and Neck Squamous Cell Carcinoma, HNSCC, PDS0101, Versamune, PDS01ADC, IL-12, Keytruda, Pembrolizumab, Clinical Trials, Phase 3, Phase 2, Biotechnology, Cancer Treatment, Infectimune, Universal Flu Vaccine, Going Concern, SEC Filing, 10-Q